AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News – Endpoints News

by

  1. AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News Endpoints News
  2. AZ’s Tagrisso plus chemo triumphs in EGFR-mutated lung cancer FiercePharma
  3. Osimertinib and Chemotherapy Improves PFS in Advanced EGFRm NSCLC Targeted Oncology
  4. TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial Business Wire
  5. Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
  6. View Full Coverage on Google News

Read original article here

Leave a Comment